APO Research
Talk to an analyst

APO RESEARCH · REPORT

Canine Arthritis Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Canine Arthritis Therapeutics Market Outlook and Growth Opportunities 2026

2 January 2026197 pages

Choose your research edition.

Industry ResearchCanine Arthritis Therapeutics Industry Research Report 2026112 pages · $2,950 USDIndustry Growth & TrendsGlobal Canine Arthritis Therapeutics Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Canine Arthritis Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Canine Arthritis Therapeutics Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Canine Arthritis Therapeutics Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Canine Arthritis Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Canine Arthritis Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Canine Arthritis Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Canine Arthritis Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Canine Arthritis Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Canine Arthritis Therapeutics market include Zoetis Inc, VetStem Biopharma, Vetoquinol S.A., Norbrook Laboratories Limited, Elanco, Dechra Pharmaceuticals Plc, Boehringer Ingelheim and Aratana Therapeutics Inc, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Canine Arthritis Therapeutics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Canine Arthritis Therapeutics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Canine Arthritis Therapeutics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Canine Arthritis Therapeutics market.

Canine Arthritis Therapeutics Segment by Company

Zoetis Inc

VetStem Biopharma

Vetoquinol S.A.

Norbrook Laboratories Limited

Elanco

Dechra Pharmaceuticals Plc

Boehringer Ingelheim

Aratana Therapeutics Inc

Canine Arthritis Therapeutics Segment by Type

Stem Cell Therapy

Non-Steroidal Anti-Inflammatory Drugs

Opioids

Canine Arthritis Therapeutics Segment by Application

Retail Pharmacies

Veterinary Hospitals and Clinics

Drug Stores

Canine Arthritis Therapeutics Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Canine Arthritis Therapeutics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Canine Arthritis Therapeutics key companies, revenue, market share, and recent developments.

3. To split the Canine Arthritis Therapeutics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Canine Arthritis Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Canine Arthritis Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze Canine Arthritis Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Canine Arthritis Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Canine Arthritis Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Canine Arthritis Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Canine Arthritis Therapeutics industry.

Chapter 3: Detailed analysis of Canine Arthritis Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Canine Arthritis Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Canine Arthritis Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Canine Arthritis Therapeutics Industry Trends Table 2. Canine Arthritis Therapeutics Industry Drivers Table 3. Canine Arthritis Therapeutics Industry Opportunities and Challenges Table 4. Canine Arthritis Therapeutics Industry Restraints Table 5. Global Canine Arthritis Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Canine Arthritis Therapeutics Revenue Share by Company (2021-2026) Table 7. Global Canine Arthritis Therapeutics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Canine Arthritis Therapeutics Key Company Manufacturing Base & Headquarters Table 9. Global Canine Arthritis Therapeutics Company, Product Type & Application Table 10. Global Canine Arthritis Therapeutics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Canine Arthritis Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Stem Cell Therapy Table 15. Significant Companies of Non-Steroidal Anti-Inflammatory Drugs Table 16. Significant Companies of Opioids Table 17. Global Canine Arthritis Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Canine Arthritis Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Canine Arthritis Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Canine Arthritis Therapeutics Sales Value Share by Type (2021-2026) Table 21. Global Canine Arthritis Therapeutics Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Retail Pharmacies Table 23. Significant Companies of Veterinary Hospitals and Clinics Table 24. Significant Companies of Drug Stores Table 25. Global Canine Arthritis Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Canine Arthritis Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Canine Arthritis Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Canine Arthritis Therapeutics Sales Value Share by Application (2021-2026) Table 29. Global Canine Arthritis Therapeutics Sales Value Share by Application (2027-2032) Table 30. Global Canine Arthritis Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Canine Arthritis Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Canine Arthritis Therapeutics Sales Value Share by Region (2021-2026) Table 33. Global Canine Arthritis Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Canine Arthritis Therapeutics Sales Value Share by Region (2027-2032) Table 35. Global Canine Arthritis Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Canine Arthritis Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Canine Arthritis Therapeutics Sales Value Market Share by Country (2021-2026) Table 38. Global Canine Arthritis Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Canine Arthritis Therapeutics Sales Value Market Share by Country (2027-2032) Table 40. Zoetis Inc Company Information Table 41. Zoetis Inc Business Overview Table 42. Zoetis Inc Canine Arthritis Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Zoetis Inc Canine Arthritis Therapeutics Product Portfolio Table 44. Zoetis Inc Recent Development Table 45. VetStem Biopharma Company Information Table 46. VetStem Biopharma Business Overview Table 47. VetStem Biopharma Canine Arthritis Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. VetStem Biopharma Canine Arthritis Therapeutics Product Portfolio Table 49. VetStem Biopharma Recent Development Table 50. Vetoquinol S.A. Company Information Table 51. Vetoquinol S.A. Business Overview Table 52. Vetoquinol S.A. Canine Arthritis Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Vetoquinol S.A. Canine Arthritis Therapeutics Product Portfolio Table 54. Vetoquinol S.A. Recent Development Table 55. Norbrook Laboratories Limited Company Information Table 56. Norbrook Laboratories Limited Business Overview Table 57. Norbrook Laboratories Limited Canine Arthritis Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Norbrook Laboratories Limited Canine Arthritis Therapeutics Product Portfolio Table 59. Norbrook Laboratories Limited Recent Development Table 60. Elanco Company Information Table 61. Elanco Business Overview Table 62. Elanco Canine Arthritis Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Elanco Canine Arthritis Therapeutics Product Portfolio Table 64. Elanco Recent Development Table 65. Dechra Pharmaceuticals Plc Company Information Table 66. Dechra Pharmaceuticals Plc Business Overview Table 67. Dechra Pharmaceuticals Plc Canine Arthritis Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Dechra Pharmaceuticals Plc Canine Arthritis Therapeutics Product Portfolio Table 69. Dechra Pharmaceuticals Plc Recent Development Table 70. Boehringer Ingelheim Company Information Table 71. Boehringer Ingelheim Business Overview Table 72. Boehringer Ingelheim Canine Arthritis Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Boehringer Ingelheim Canine Arthritis Therapeutics Product Portfolio Table 74. Boehringer Ingelheim Recent Development Table 75. Aratana Therapeutics Inc Company Information Table 76. Aratana Therapeutics Inc Business Overview Table 77. Aratana Therapeutics Inc Canine Arthritis Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Aratana Therapeutics Inc Canine Arthritis Therapeutics Product Portfolio Table 79. Aratana Therapeutics Inc Recent Development Table 80. Research Programs/Design for This Report Table 81. Authors List of This Report Table 82. Secondary Sources Table 83. Primary Sources List of Figures Figure 1. Canine Arthritis Therapeutics Product Image Figure 2. Global Canine Arthritis Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Canine Arthritis Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global Canine Arthritis Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Stem Cell Therapy Image Figure 8. Non-Steroidal Anti-Inflammatory Drugs Image Figure 9. Opioids Image Figure 10. Global Canine Arthritis Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Canine Arthritis Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Canine Arthritis Therapeutics Sales Value Share by Type (2021-2032) Figure 13. Retail Pharmacies Image Figure 14. Veterinary Hospitals and Clinics Image Figure 15. Drug Stores Image Figure 16. Global Canine Arthritis Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Canine Arthritis Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Canine Arthritis Therapeutics Sales Value Share by Application (2021-2032) Figure 19. Global Canine Arthritis Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Canine Arthritis Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Canine Arthritis Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 22. North America Canine Arthritis Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Canine Arthritis Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Canine Arthritis Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Canine Arthritis Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Canine Arthritis Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Canine Arthritis Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 28. South America Canine Arthritis Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Canine Arthritis Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Canine Arthritis Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Stem Cell Therapy
  • Non-Steroidal Anti-Inflammatory Drugs
  • Opioids
Applications
  • Retail Pharmacies
  • Veterinary Hospitals and Clinics
  • Drug Stores
Companies covered
  • Zoetis Inc
  • VetStem Biopharma
  • Vetoquinol S.A.
  • Norbrook Laboratories Limited
  • Elanco
  • Dechra Pharmaceuticals Plc
  • Boehringer Ingelheim
  • Aratana Therapeutics Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Canine Arthritis Therapeutics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Canine Arthritis Therapeutics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Canine Arthritis Therapeutics Market Dynamics
  1. 2.1 Canine Arthritis Therapeutics Industry Trends
  2. 2.2 Canine Arthritis Therapeutics Industry Drivers
  3. 2.3 Canine Arthritis Therapeutics Industry Opportunities and Challenges
  4. 2.4 Canine Arthritis Therapeutics Industry Restraints
3 Canine Arthritis Therapeutics Market by Company
  1. 3.1 Global Canine Arthritis Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global Canine Arthritis Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global Canine Arthritis Therapeutics Company Ranking (2024-2026)
  4. 3.4 Global Canine Arthritis Therapeutics Company Manufacturing Base and Headquarters
  5. 3.5 Global Canine Arthritis Therapeutics Company Product Type and Application
  6. 3.6 Global Canine Arthritis Therapeutics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Canine Arthritis Therapeutics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Canine Arthritis Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Canine Arthritis Therapeutics Market by Type
  1. 4.1 Canine Arthritis Therapeutics Type Introduction
  2. 4.1.1 Stem Cell Therapy
  3. 4.1.2 Non-Steroidal Anti-Inflammatory Drugs
  4. 4.1.3 Opioids
  5. 4.2 Global Canine Arthritis Therapeutics Sales Value by Type
  6. 4.2.1 Global Canine Arthritis Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Canine Arthritis Therapeutics Sales Value by Type (2021-2032)
  8. 4.2.3 Global Canine Arthritis Therapeutics Sales Value Share by Type (2021-2032)
5 Canine Arthritis Therapeutics Market by Application
  1. 5.1 Canine Arthritis Therapeutics Application Introduction
  2. 5.1.1 Retail Pharmacies
  3. 5.1.2 Veterinary Hospitals and Clinics
  4. 5.1.3 Drug Stores
  5. 5.2 Global Canine Arthritis Therapeutics Sales Value by Application
  6. 5.2.1 Global Canine Arthritis Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Canine Arthritis Therapeutics Sales Value by Application (2021-2032)
  8. 5.2.3 Global Canine Arthritis Therapeutics Sales Value Share by Application (2021-2032)
6 Canine Arthritis Therapeutics Regional Value Analysis
  1. 6.1 Global Canine Arthritis Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Canine Arthritis Therapeutics Sales Value by Region (2021-2032)
  3. 6.2.1 Global Canine Arthritis Therapeutics Sales Value by Region: 2021-2026
  4. 6.2.2 Global Canine Arthritis Therapeutics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Canine Arthritis Therapeutics Sales Value (2021-2032)
  7. 6.3.2 North America Canine Arthritis Therapeutics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Canine Arthritis Therapeutics Sales Value (2021-2032)
  10. 6.4.2 Europe Canine Arthritis Therapeutics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Canine Arthritis Therapeutics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Canine Arthritis Therapeutics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Canine Arthritis Therapeutics Sales Value (2021-2032)
  16. 6.6.2 South America Canine Arthritis Therapeutics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Canine Arthritis Therapeutics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Canine Arthritis Therapeutics Sales Value Share by Country, 2025 VS 2032
7 Canine Arthritis Therapeutics Country-level Value Analysis
  1. 7.1 Global Canine Arthritis Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Canine Arthritis Therapeutics Sales Value by Country (2021-2032)
  3. 7.2.1 Global Canine Arthritis Therapeutics Sales Value by Country (2021-2026)
  4. 7.2.2 Global Canine Arthritis Therapeutics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Canine Arthritis Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Canine Arthritis Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Canine Arthritis Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Zoetis Inc
  2. 8.1.1 Zoetis Inc Company Information
  3. 8.1.2 Zoetis Inc Business Overview
  4. 8.1.3 Zoetis Inc Canine Arthritis Therapeutics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Zoetis Inc Canine Arthritis Therapeutics Product Portfolio
  6. 8.1.5 Zoetis Inc Recent Developments
  7. 8.2 VetStem Biopharma
  8. 8.2.1 VetStem Biopharma Company Information
  9. 8.2.2 VetStem Biopharma Business Overview
  10. 8.2.3 VetStem Biopharma Canine Arthritis Therapeutics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 VetStem Biopharma Canine Arthritis Therapeutics Product Portfolio
  12. 8.2.5 VetStem Biopharma Recent Developments
  13. 8.3 Vetoquinol S.A.
  14. 8.3.1 Vetoquinol S.A. Company Information
  15. 8.3.2 Vetoquinol S.A. Business Overview
  16. 8.3.3 Vetoquinol S.A. Canine Arthritis Therapeutics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Vetoquinol S.A. Canine Arthritis Therapeutics Product Portfolio
  18. 8.3.5 Vetoquinol S.A. Recent Developments
  19. 8.4 Norbrook Laboratories Limited
  20. 8.4.1 Norbrook Laboratories Limited Company Information
  21. 8.4.2 Norbrook Laboratories Limited Business Overview
  22. 8.4.3 Norbrook Laboratories Limited Canine Arthritis Therapeutics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Norbrook Laboratories Limited Canine Arthritis Therapeutics Product Portfolio
  24. 8.4.5 Norbrook Laboratories Limited Recent Developments
  25. 8.5 Elanco
  26. 8.5.1 Elanco Company Information
  27. 8.5.2 Elanco Business Overview
  28. 8.5.3 Elanco Canine Arthritis Therapeutics Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Elanco Canine Arthritis Therapeutics Product Portfolio
  30. 8.5.5 Elanco Recent Developments
  31. 8.6 Dechra Pharmaceuticals Plc
  32. 8.6.1 Dechra Pharmaceuticals Plc Company Information
  33. 8.6.2 Dechra Pharmaceuticals Plc Business Overview
  34. 8.6.3 Dechra Pharmaceuticals Plc Canine Arthritis Therapeutics Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Dechra Pharmaceuticals Plc Canine Arthritis Therapeutics Product Portfolio
  36. 8.6.5 Dechra Pharmaceuticals Plc Recent Developments
  37. 8.7 Boehringer Ingelheim
  38. 8.7.1 Boehringer Ingelheim Company Information
  39. 8.7.2 Boehringer Ingelheim Business Overview
  40. 8.7.3 Boehringer Ingelheim Canine Arthritis Therapeutics Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Boehringer Ingelheim Canine Arthritis Therapeutics Product Portfolio
  42. 8.7.5 Boehringer Ingelheim Recent Developments
  43. 8.8 Aratana Therapeutics Inc
  44. 8.8.1 Aratana Therapeutics Inc Company Information
  45. 8.8.2 Aratana Therapeutics Inc Business Overview
  46. 8.8.3 Aratana Therapeutics Inc Canine Arthritis Therapeutics Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Aratana Therapeutics Inc Canine Arthritis Therapeutics Product Portfolio
  48. 8.8.5 Aratana Therapeutics Inc Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst